About Us
Chief's Message
- Message from the Chief
- Division Brochure
Meet the Team
Conditions & Procedures
Patient Center
Transplant Experiences
- Patient Stories
Kidney Transplant
- New Patient Information and Forms
- Patient Referrals
Liver Transplant
- New Patient Information & Forms
- Liver Transplant Handbook
- Patient Referrals
Resources
- Helpful Links
- Organ Donation
- UCTV Transplant Videos
Clinics
UCSF Medical Center
- Kidney Transplant
- Liver Transplant
- Pancreas Transplant
Benioff Children's Hospital
- Kidney Transplant
- Liver Transplant
Other Locations
- Liver Transplant
- Kidney Transplant
Education & Training
Research
Clinical Research
- Overview
- Clinical Trials
- Clinical Research Team
- T32 Research Training Program in Transplant Surgery
Division Labs
- Ischemic Organ Injury Lab
- Immunogenetics and Transplantation Laboratory (ITL)
- Sarwal Lab
- Tang Lab
- Transplantation Research Lab
Research Advances
- Frontiers of Clinical Research: Islet Transplantation
- Transplant Surgery Brochure
News & Events
Rajalingam Raja, Ph.D., FRCPath., D(ABHI)
- Clinical Professor of Surgery
- Director, Immunogenetics and Transplantation Laboratory
Contact Information
UCSF Immunogenetics and Transplantation Laboratory
Department of Surgery, Box 0508
3333 California Street, Suite 150
San Francisco, CA 94143
415-476-3883 Phone
415-476-0379 Fax
Rajalingam.Raja@ucsf.edu
Department of Surgery, Box 0508
3333 California Street, Suite 150
San Francisco, CA 94143
415-476-3883 Phone
415-476-0379 Fax
Rajalingam.Raja@ucsf.edu
Education
University of Madras, India. B.Sc., 1984
Bharathiyar University, India. M.Sc., 1988
University of Madras, India. M.Phil., 1989
All India Institute of Medical Sciences, India. Ph.D., 1996
Biography
Dr. Rajalingam Raja serves as the Laboratory Director, Clinical Consultant and Technical Supervisor for the UCSF Immunogenetics and Transplantation Laboratory. Dr. Raja received his Ph.D. from the Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi. Six-years of pre-doctoral studies in HLA diversity, followed by six-years of post-doctoral research in NK cell immunogenetics at Stanford, plus eighteen-years of experience in clinical histocompatibility laboratory directorship in the high volume transplant centers at UCLA and UCSF have shaped Dr. Raja into one of the uniquely experienced investigators committed to the fields of histocompatibility, immunogenetics and transplant immunology.
Awards & Honors
Award
Confired By
Date
Research Overview
Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants, autoimmunity and the maintenance of pregnancy. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to the unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and they map to distinct human chromosomes (Chromosomes 19 and 6, respectively).
KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially could influence the health and disease status of a given individual. The overall goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 85
Data provided by UCSF Profiles, powered by CTSI
- Diego VP, Luu BW, Hofmann M, Dinh LV, Almeida M, Powell JS, Rajalingam R, Peralta JM, Kumar S, Curran JE, Sauna ZE, Kellerman R, Park Y, Key NS, Escobar MA, Huynh H, Verhagen AM, Williams-Blangero S, Lehmann PV, Maraskovsky E, Blangero J, Howard TE. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thromb Haemost. 2020 01; 18(1):201-216. View in PubMed
- Roll GR, Webber AB, Gae DH, Laszik Z, Tavakol M, Mayen L, Cunniffe K, Syed S, Hirose R, Freise C, Feng S, Roberts JP, Ascher NL, Stock PG, Rajalingam R. A Virtual Crossmatch-based Strategy Facilitates Sharing of Deceased Donor Kidneys for Highly Sensitized Recipients. Transplantation. 2020 06; 104(6):1239-1245. View in PubMed
- Gupta N, Henry RG, Kang SM, Strober J, Lim DA, Ryan T, Perry R, Farrell J, Ulman M, Rajalingam R, Gage A, Huhn SL, Barkovich AJ, Rowitch DH. Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease. Stem Cell Reports. 2019 08 13; 13(2):254-261. View in PubMed
- Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina M, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019 09 19; 134(12):924-934. View in PubMed
- Gao Y, Twigg AR, Hirose R, Roll GR, Nowacki AS, Maytin EV, Vidimos AT, Rajalingam R, Arron ST. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant. JAMA Dermatol. 2019 03 01; 155(3):307-314. View in PubMed
- View All Publications